Brief: ESSA Pharma Insiders Establish Automatic Securities Disposition Plans
Brief: ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy And Combination Therapy Clinical Development
Essa Pharma Inc Reports Results For The Quarter Ended In March: Earnings Summary
Brief: Essa Pharma Provides Corporate Update And Reports Financial Results For Fiscal Second Quarter Ended March 31, 2022
Essa Pharma Inc Expected To Post A Loss Of 25 Cents A Share: Earnings Preview
Brief: Essa Pharma Posts Loss Of 21 Cents Per Share
Brief: Essa Pharma Posts Q1 Loss Of 21 Cents Per Share
Brief: Essa Pharma Announces First Patient Dosed In A Phase 1/2 Clinical Trial Of EPI-7386
Gambia's President Barrow takes slim, early lead as vote-tallies continue (updated)
Brief: ESSA Pharma Reports Q4 Loss Per Share $0.20
Brief: ESSA Pharma Inc And Caris Life Sciences Announce Liquid Biopsy Profiling Collaboration
U.S. RESEARCH ROUNDUP-CF Industries Holdings, DXC Technology Co, Rackspace Technology
Essa Pharma Inc Reports Results For The Quarter Ended In June: Earnings Summary
Brief: Essa Pharma Inc - QTRLY Loss Per Share $0.21
Brief: Essa Pharma Reports Q3 Loss Per Share Of $0.21
Essa Pharma Inc Expected To Post A Loss Of 26 Cents A Share: Earnings Preview
Essa Pharma Inc Expected To Post A Loss Of 26 Cents A Share: Earnings Preview
Essa Pharma Inc Expected To Post A Loss Of 26 Cents A Share: Earnings Preview
Essa Pharma Inc Expected To Post A Loss Of 26 Cents A Share: Earnings Preview